# EDGAR Filing Document

**Accession Number:** 0001965964
**File Stem:** 0001193125-26-223925
**Filing Date:** 2026-5
**Character Count:** 8205
**Document Hash:** 8356ea7053d9ca7632abd59a485c2703
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-223925.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001193125-26-223925

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BELITE BIO, INC
- **CENTRAL INDEX KEY:** 0001889109
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93970
- **FILM NUMBER:** 26978487

**BUSINESS ADDRESS:**
- **STREET 1:** 12750 HIGH BLUFF DRIVE SUITE 475
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 858-246-6240

**MAIL ADDRESS:**
- **STREET 1:** 12750 HIGH BLUFF DRIVE SUITE 475
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lin Yu-Hsin
- **CENTRAL INDEX KEY:** 0001965964

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**MAIL ADDRESS:**
- **STREET 1:** 12750 HIGH BLUFF DRIVE, SUITE 475
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LIn Yu-Hsin
- **DATE OF NAME CHANGE:** 20230215

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Issuer:** BELITE BIO, INC

**Title of Class of Securities:** Ordinary shares, par value US$0.0001 per share

**CUSIP Number:** —

**Date of Event Which Requires Filing of this Statement:** 03/31/2026

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [x] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Yu-Hsin Lin | Names of Reporting Persons<br>Yu-Hsin Lin |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>C3 | Citizenship or Place of Organization<br>C3 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>1253935 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>1253935 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1253935 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1253935 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [x] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [x] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>3.1% | Percent of Class Represented by Amount in Row (9)<br>3.1% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** Notes to row 9: Yu-Hsin Lin is deemed to hold a total of 2,728,462 Ordinary Shares in Belite Bio, Inc, among which (i) 353,083 Ordinary Shares are directly held by Yu-Hsin Lin; (ii) 900,852 Ordinary Shares underlying share options and restricted stock units granted to Yu-Hsin Lin that are vested or will be vested within 60 days of March 31, 2026 are deemed to be held by Yu-Hsin Lin; and (iii) 1,474,527 Ordinary Shares are indirectly held by Yu-Hsin Lin through his shareholding in Lin BioScience, Inc., a public company listed on the OTC market in Taiwan (stock code: 6696.TW) and the parent company of Lin Bioscience International Ltd. Yu-Hsin Lin disclaims investment and disposition power of the 1,474,527 Ordinary Shares indirectly held by Yu-Hsin Lin through Lin BioScience, Inc. and Lin Bioscience International Ltd.

Notes to row 11: The percentage is calculated by dividing the number of Ordinary Shares beneficially owned by Yu-Hsin Lin by the aggregate of (i) 40,085,091 Ordinary Shares issued and outstanding as of March 31, 2026 as provided by the Issuer; and (ii) 900,852 Ordinary Shares underlying share options and restricted stock units granted to Yu-Hsin Lin that are vested or will be vested within 60 days of March 31, 2026 and are deemed to be beneficially owned by Yu-Hsin Lin.

---

**Item 1(a). Name of Issuer:**
BELITE BIO, INC

**Item 1(b). Address of Issuer's Principal Executive Offices:**
12750 High Bluff Drive Suite 475, San Diego, CA 92130, United States of America

**Item 2(a). Name of Person Filing:**
This Schedule 13G is filed on behalf of Yu-Hsin Lin ("Reporting Person")

**Item 2(b). Address of Principal Business Office:**
The business address of the Reporting Person is 36F., No. 68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan

**Item 2(c). Citizenship:**
Yu-Hsin Lin is a citizen of Australia

**Item 2(d). Title of Class of Securities:**
Ordinary shares, par value US$0.0001 per share

**Item 2(e). CUSIP Number:**
—

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

1,253,935

**(b) Percent of class:**

3.1 %

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

1,253,935

**(ii) Shared power to vote or to direct the vote:**

0

**(iii) Sole power to dispose or to direct the disposition of:**

1,253,935

**(iv) Shared power to dispose or to direct the disposition of:**

0

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Yu-Hsin Lin**

**Date:** 05/14/2026

**By:** /s/ Yu-Hsin Lin

**Name & Title:** Yu-Hsin Lin, Chief Executive Officer and Chairman